Full Press Release Details
NanoVibronix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted
Basis on August 12, 2025
TYLER, TX, August 8, 2025 (Business Wire)
- NanoVibronix, Inc. (NASDAQ: NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing
in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001
per share (the "common stock") at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will
become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company's common stock will continue to be traded
on the Nasdaq Capital Market under the symbol NAOV and will begin trading on a split-adjusted basis when the market opens on Tuesday,
August 12, 2025. The new CUSIP number for the common stock following the reverse stock split is 63008J884.
At a special meeting of stockholders, as adjourned
and held on July 17, 2025, the Company's stockholders granted the Company's Board of Directors the discretion to effect a
reverse stock split of the Company's common stock through an amendment to its Amended and Restated Certificate of Incorporation,
as amended, at a ratio of not less than 1-for-2 and not more than 1-for-50, with such ratio to be determined by the Company's Board
At the effective time of the reverse stock split,
every ten (10) shares of the Company's issued and outstanding common stock will be converted automatically into one issued and outstanding
share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have
their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of
the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the
Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders
uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the
reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the
reverse stock split will be rounded up to the nearest whole number of shares. The reverse stock split will reduce the number of shares
of the Company's common stock outstanding from 7,968,868 shares to approximately 796,887 shares. Proportional adjustments will be
made to the number of shares of the Company's common stock issuable upon exercise or conversion of the Company's equity awards,
warrants and other convertible securities, as well as the applicable exercise or conversion price thereof. Stockholders with shares in
brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions
to the Company's transfer agent, VStock Transfer, LLC, at (212) 828-8436.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical
technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered
in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct technology platforms:
NanoVibronix aims to advance standards in non-invasive
therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a
range of healthcare environments.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of
future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties
associated with: (i) the effect that the reverse stock split may have on the price of the Company's common stock; (ii) the Company's
ability to maintain its listing on the Nasdaq Capital Market; (iii) market acceptance of the Company's existing and new products
or lengthy product delays in key markets; (iv) negative or unreliable clinical trial results; (v) inability to secure regulatory approvals
for the sale of the Company's products; (vi) intense competition in the medical device industry from much larger, multinational
companies; (vii) product liability claims; (viii) product malfunctions; (ix) the Company's limited manufacturing capabilities and
reliance on subcontractor assistance; (x) insufficient or inadequate reimbursements by governmental and/or other third party payers for
the Company's products; (xi) the Company's ability to successfully obtain and maintain intellectual property protection covering
its products; (xii) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xiii) the
Company's reliance on single suppliers for certain product components, (xiv) the need to raise additional capital to meet our future
business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult
to obtain; (xv) the Company's conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign
currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and
political and/or economic instabilities in specific jurisdictions; and (xvi) market and other conditions. More detailed information about
the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 10-K and its Quarterly
Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at:
http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events, or otherwise, except as required by law.
Brett Maas, Managing Principal, Hayden IR, LLC
SOURCE: NanoVibronix, Inc.